While much of the social and political attention surrounding the nationwide opioid epidemic has focused on the dramatic increase in overdose deaths among white, middle-class, suburban and rural users, the impact of the epidemic in Black communities has largely been unrecognized. Though rates of opioid use at the national scale are higher for whites than they are for Blacks, rates of increase in opioid deaths have been rising more steeply among Blacks (43%) than whites (22%) over the last five years. Moreover, the rate of opioid overdose deaths among Blacks already exceeds that of whites in several states. The lack of discussion of Black overdose deaths in the national opioid discourse further marginalizes Black people, and is highly consistent with a history of framing the addictions of people of color as deserving of criminal punishment, rather than worthy of medical treatment. This article argues that, because racial inequalities are embedded in American popular and political cultures as well as in medicine, the federal and state governments should develop more culturally targeted programs to benefit Black communities in the opioid crisis. Such programs include the use of faith-based organizations to deliver substance use prevention and treatment services, the inclusion of racial impact assessments in the implementation of drug policy proposals, and the formal consideration of Black people's interaction with the criminal justice system in designing treatment options.
R. A.Ruddet al., “Increases in Drug and Opioid-Involved Overdose Deaths — United States, 2010-2015,”MMWR Morbidity and Mortality Weekly Report65, nos. 50-51 (2016): 1445–1452, at 1445.
T.J.Cicero, M.S.Ellis and Z.A.Kasper, “Increased Use of Heroin as an Initiating Opioid of Abuse,”Addictive Behaviors74, (2017): 63-66.
5.
National Center for Health Statistics, Center for Disease Control and Prevention, U.S. Department of Health and Human Services, “Drug Overdose Deaths in the United States, 1999–2015,”NCHS Data Brief, no. 273 (Feb. 2017), available at <https://www.cdc.gov/nchs/data/databriefs/db273.pdf> (last visited May 9, 2018).
See generallyE.Drucker, “Population Impact of Mass Incarceration under New York’s Rockefeller Drug Laws: An Analysis of Years of Life Lost,”Journal of Urban Health Bulletin of the New York Academy of Medicine79, no. 3 (2002): 434-444.
8.
See Rudd, supra note 2.
9.
It is important to note that overdose deaths from opioids alone account for a minority of the thousands of opioid-related deaths. Many overdose deaths are caused when people combine an opioid with another sedative, an antihistamine, or a benzodiazepine. See Hart, supra note 6.
10.
National Center for Health Statistics, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, “Compressed Mortality File 1968-1978 on CDC WONDER Online Database,”available at <http://wonder.cdc.gov/cmf-icd8.html> (last visited May 9, 2018).
11.
F.Modaraiet al., “Relationship of Opioid Prescription Sales and Overdoses, North Carolina,’Drug and Alcohol Dependence132, no. 1 (2013): 81-86; A.S. Bohnert et al., “Association Between Opioid Prescribing Patterns and Opioid Overdose-Related Deaths,” JAMA 305, no. 13 (2011): 1315-1321.
12.
J.Schottenfeld, S.Waldman, A.Gluck, and D.Tobin, “Pain and Addiction in Specialty and Primary Care: The Bookends of a Crisis,”Journal of Law, Medicine & Ethics46, no. 2 (2018): 220-237.
13.
Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services, Results from the 2008 National Survey on Drug Use and Health: National Findings, Sept. 2009, available at <http://www.dpft.org/resources/NSDUHresults2008.pdf> (last visited May 9, 2018).
Data from NCHS, National Vital Statistics System, Mortality. Deaths are classified using the International Classification of Diseases, Tenth Revision. Drug overdose deaths are identified using underlying cause-of-death codes X40–X44, X60–X64, X85, and Y10–Y14. Deaths for Hispanic persons may be underreported by about 5%.
Id. See alsoDrug Enforcement Administration (DEA), “DEA Issues Nationwide Alert on Fentanyl as Threat to Health and Public Safety,”Mar. 18, 2015, available at <http://www.dea.gov/divisions/hq/2015/hq031815.shtml> (last visited May 9, 2018).
J.Katz and A.Goodnough, “The Opioid Crisis Is Getting Worse, Particularly for Black Americans,”New York Times, Dec. 22, 2017.
34.
See Office of the Chief Medical Examiner, supra note 25.
35.
See Office of the Chief Medical Examiner, supra note 25.
36.
See Bechteler and Kane-Willis, supra note 20.
37.
See Bechteler and Kane-Willis, supra note 20.
38.
While the CDC analyzes synthetic opioids (other than metha-done) separately from other prescription opioids, it does not distinguish fentanyl from other synthetic opioids, such as tramadol, within this category. The CDC also does not distinguish pharmaceutical fentanyl from illegally-made fentanyl.
39.
Data are “suppressed” when the data meet the criteria for confidentiality constraints. Death rates are flagged as “unreliable” when the rate is calculated with a numerator of 20 or less.
40.
National Center for Health Statistics, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, “Multiple Cause of Death 1999-2016 on CDC WONDER Online Database,”available at <http://wonder.cdc.gov/mcd-icd10.html> (last visited May 9, 2018). Deaths are classified using the International Classification of Diseases, Tenth Revision. Drug overdose deaths are identified using multiple cause-of-death code T40.4 for “synthetic opioids other than methadone.”
41.
Grey cells indicate states in which rates of opioid overdose deaths among Black Americans exceed those of white Americans.
42.
For example, the 2016 Drug Report from the Cuyahoga County Medical Examiner’s Office offers a demographic analysis of overdose deaths by fentanyl, fentanyl combined with heroin, fentanyl combined with cocaine, and fentanyl combined with both heroin and cocaine. See Cuyahoga County Medical Examiner’s Office, supra note 30.
C P.Jones, “Levels of Racism: A Theoretic Framework and a Gardener’s Tale,”American Journal of Public Health90, no. 8 (2000): 1212–1215.
45.
K.M.Hoffmanet al., “Racial Bias in Pain Assessment and Treatment Recommendations, and False Beliefs about Biological Differences between Blacks and Whites,”Proceedings of the National Academy of Sciences113, no. 16 (2016): 4296-4301; A.J. Kposowa and G.T. Tsunokai, “Searching for Relief: Racial Differences in Treatment of Patients with Back Pain,” Race and Society 5, no. 2 (2002): 193-223; K.H. Todd et al., “Ethnicity and Analgesic Practice,” Annals of Emergency Medicine 35, no. 1 (2000): 11-16.
46.
C.R.Greenet al., “The Unequal Burden of Pain: Confronting Racial and Ethnic Disparities in Pain,”Pain Medicine4, no. 3 (2003): 277–294; R. Bernabei et al., “Management of Pain in Elderly Patients with Cancer,” JAMA, 279, no. 23 (1998): 1877-1882. (Black nursing home residents 63% less likely than similarly situated whites to receive opioids for cancer pain.)
47.
S. H.Meghaniet al., “Time to Take Stock: A Meta-Analysis and Systematic Review of Analgesic Treatment Disparities for Pain in the United States,”Pain Medicine13, no. 2 (2012): 150-174.
48.
See Cicero et al., supra note 4.
49.
See Cicero et al., supra note 4.
50.
See Cicero et al., supra note 4.
51.
Dowellet al., Opinion Editorial, “Underlying Factors in Drug Overdose Death,”JAMA318, no. 23 (2017): 2295-2296.
52.
T.J.Ciceroet al., “The Changing Face of Heroin Use in the United States: A Retrospective Analysis of the Past 50 Years,”JAMA Psychiatry71, no. 7 (2014): 821-826.
53.
S.G.Marset al., “Every ‘Never’ I Ever Said Came True: Transitions from Opioid Pills to Heroin Injecting,”International Journal of Drug Policy25, no. 2 (2014): 257-266; T.J. Cicero et al., “Effect of Abuse-Deterrent Formulation of OxyContin,” N. Engl. J. Med. 367, no. 2 (2012): 187-189; S.E. Lankenau et al., “Initiation into Prescription Opioid Misuse Amongst Young Injection Drug Users,” International Journal of Drug Policy 23, no. 1 (2012): 37-44; N.D. Volkow, “America’s Addiction to Opioids: Heroin and Prescription Drug Abuse,” Testimony to Senate Caucus on International Narcotics Control, May 14, 2014, available at <https://www.drugabuse.gov/about-nida/legislative-activities/testimony-to-congress/2016/americas-addiction-to-opioids-heroin-prescription-drug-abuse> (last visited May 9, 2018).
Bureau of Justice Statistics, Office of Justice Programs, U.S. Department of Justice, Drug Offenders in Federal Prison: Estimates of Characteristics Based on Linked Data, SPECIAL REPORT, Oct. 2015, available at <https://www.bjs.gov/content/pub/pdf/dofp12.pdf> (last visited May 9, 2018).
S.A.Tsimbinos, “Is It Time to Change the Rockefeller Drug Laws?”St. John’s Journal of Legal Comment13, no. 3 (1999): 613-634, at 613 (stating that Governor Rockefeller and the Legislature enacted toughest drug laws in country in response to increased drug use); T.M. Quinn and G.T. McLaughlin, “The Evolution and Present Status of New York Drug Control Legislation,” Buffalo Law Review 22, no. 3 (1973): 705-736, at 733 (stating that Rockefeller Drug Laws evidence ‘strict law enforcement attitude’ regarding drug crime in New York).
61.
J.E.Underwood and W.J.Daniels, Governor Rockefeller in New York: The Apex of Pragmatic Liberalism in the United States (Westport: Greenwood Press, 1982): at 139.
R.H.Connery and G.Benjamin, Rockefeller of New York: Executive Power in the Statehouse (Ithaca, N.Y.: Cornell University Press, 1979): at 272.
66.
E.Drucker, “Population Impact of Mass Incarceration under New York’s Rockefeller Drug Laws: An Analysis of Years of Life Lost,”Journal of Urban Health Bulletin of the New York Academy of Medicine79, no. 3 (2002): 434-444.
67.
Id. See alsoL.R.Nakdai, “Are New York’s Rockefeller Drug Laws Killing the Messenger for the Sake of the Message,”Hofstra Law Review30, no. 2 (2001): 557-587.
68.
See generallyE.J.Maggio, “New York’s Rockefeller Drug Laws, Then and Now,”NYSBA Journal78, no. 9 (2006): 30-34.
69.
Anti-Drug Abuse Act of 1986, Pub. L. No. 99-570, 100 Stat. 3207 (codified in various sections of 21 U.S.C.).
70.
See generallyC.L.Hart, High Price: A Neuroscientist’s Journey of Self-Discovery That Challenges Everything You Know About Drugs and Society (New York: HarperCollins Publishers, 2013) [herein after Hart, High Price].
71.
U.S. Department of Justice, Federal Cocaine Offenses: An Analysis of Crack and Powder Penalties, Mar. 17, 2002.
M.G.Vaughnet al., “Is Crack Cocaine Use Associated with Greater Violence than Powdered Cocaine Use? Results from a National Sample,”The American Journal of Drug and Alcohol Abuse36, no. 4 (2010): 181-186.
Bureau of Justice Statistics, Office of Justice Programs, U.S. Department of Justice, Probation and Parole in the United States, 2015, Bulletin, Feb. 2, 2017, available at <https://www.bjs.gov/content/pub/pdf/ppus15.pdf> (last visited May 9, 2018).
85.
Bureau of Justice Statistics, Office of Justice Programs, U.S. Department of Justice, Drug Offenders in Federal Prison: Estimates of Characteristics Based on Linked Data, SPECIAL REPORT, Oct. 2015, available at <https://www.bjs.gov/content/pub/pdf/dofp12.pdf> (last visited May 9, 2018) [hereinafter BJS, Estimates]. See also “Inmate Race,” Federal Bureau of Prisons, available at <https://www.bop.gov/about/statistics/statistics_inmate_race.jsp> (last visited May 9, 2018).
86.
See BJS, Estimates, supra note 85.
87.
See BJS, Estimates, supra note 85.
88.
See BJS, Estimates, supra note 85. See alsoN.Werle and E.Zedillo, “We Can’t Go Cold Turkey: Why suppressing drug markets endangers society,”Journal of Law, Medicine & Ethics46, no. 2 (2018): 325-342.
89.
L.O.Gostinet al., “Reframing the Opioid Epidemic as a National Emergency,”JAMA318, no. 16 (2017): 1539-1540.
J.Netherland and H.B.Hansen, “The War on Drugs That Wasn’t: Wasted Whiteness, ‘Dirty Doctors,’ and Race in Media Coverage of Prescription Opioid Misuse,”Culture, Medicine, and Psychiatry40, no. 4 (2016): 664-686.
U.S. General Accountability Office, Youth Illicit Drug Use Prevention: DARE Long-Term Evaluations and Federal Efforts to Identify Effective Programs, Jan15. 2003, available at <https://www.gao.gov/assets/100/91676.pdf> (last visited May 9. 2018); Office of the Surgeon General, Department of Health and Human Services, Youth Violence: A Report of the Surgeon General, 2001; D. R. Lynam et al., “Project DARE: No Effects at 10-Year Follow-Up,” Journal of Consulting and Clinical Psychology 67, no. 4 (1999): 590–593.
118.
See Final Report, supra note 116 at 10.
119.
See Final Report, supra note 116 at 7.
120.
M.C.Daley, “Race, Managed Care, and the Quality of Substance Abuse Treatment,”Administration and Policy in Mental Health and Mental Health Services Research32, no. 4 (2005): 457-476; M. Alegria, G. Canino, and R. Rios, “Inequalities in Use of Specialty Mental Health Services Among Latinos, African Americans, and Non-Latino Whites,” Year Book of Psychiatry & Applied Mental Health 1 (2004): 184-185; K. Wells et al., “Ethnic Disparities in Unmet Need for Alcoholism, Drug Abuse, and Mental Health Care,” American Journal of Psychiatry 158, no. 12 (2001): 2027-2032; D. Longshore et al., “Ethnic Patterns in Drug Abuse Treatment Utilization,” The Journal of Behavioral Health Services and Research 19, no. 3 (1992): 268-277.
121.
See Final Report, supra note 116 at 24-25.
122.
See Final Report, supra note 116 at 24-25.
123.
Substance Abuse and Mental Health Services Administration, Office of the Surgeon General, U.S. Department of Health and Human Services, Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health, Nov. 2016, available at <https://addiction.surgeongeneral.gov/surgeon-generals-report.pdf> (last accessed May 9, 2018).
K.Wellset al., “Ethnic Disparities in Unmet Need for Alcoholism, Drug Abuse, and Mental Health Care,”American Journal of Psychiatry158, no. 12 (2001): 2027-2032.
126.
R. N.Lipari and C.Hager, “Substance Abuse and Mental Health Administration, Need for and Receipt of Substance Use Treatment among Blacks,”The CBHSQ Report, Feb. 21, 2013.
127.
B. LêCook and M.Alegría, “Racial-Ethnic Disparities in Substance Abuse Treatment: The Role of Criminal History and Socioeconomic Status,”Psychiatric Services62, no. 11 (2011): 1273-1281; J.L. Rounds-Bryant and J. Staab, “Patient Characteristics and Treatment Outcomes for African American, Hispanic, and White Adolescents in DATOS-A,” Journal of Adolescent Research 16, no. 6 (2001): 624-641.
128.
J.C.Barnett and M.S.Vornovitsky, U.S. Census Bureau, Health Insurance Coverage in the United States: 2015, Current Population Reports, Sept. 2016, available at <https://www.census.gov/content/dam/Census/library/publications/2016/demo/p60-257.pdf> (last visited May 9, 2018); J.R. Cummings et al., “Race/Ethnicity and Geographic Access to Medicaid Substance Use Disorder Treatment Facilities in the United States,” JAMA Psychiatry 71, no. 2 (2014): 190-196.
129.
See Cummings et al., supra note 128.
130.
I.Ayres and A.Jalal, “The Impact of Prescription Drug Monitoring Programs on U.S. Opioid Prescriptions,”Journal of Law, Medicine & Ethics46, no. 2 (2018): 387-403.
131.
J.Netherland and H.B.Hansen, “White Opioids: Pharmaceutical Race and the War on Drugs that Wasn’t,”BioSocieties12, no. 2 (2017): 217-238; H. Hansen et al., “Buprenorphine and Methadone Treatment for Opioid Dependence by Income, Ethnicity and Race of Neighborhoods in New York City,” Drug and Alcohol Dependence 164 (2016): 14-21. See also J.A. Del Real, “Opioid Addiction Knows No Color, but Its Treatment Does,” New York Times, Jan. 12, 2018, available at <https://www.nytimes.com/2018/01/12/nyregion/opioid-addiction-knows-no-color-but-its-treatment-does.html> (last visited May 9, 2018).
132.
See Barnett and Vornovitsky, supra note 128.
133.
See, e.g., J.R.Cummingset al., “Geography and the Medicaid Mental Health Care Infrastructure: Implications for Health Care Reform,”JAMA Psychiatry70, no. 10 (2013): 1084-1090; R.Y. Hsia and Y. Shen, “Rising Closures of Hospital Trauma Centers Disproportionately Burden Vulnerable Populations,” Health Affairs 30, no. 10 (2011): 1912-1920; M. Komaromy et al., “The Role of Black and Hispanic Physicians in Providing Health Care for Underserved Populations,” New England Journal of Medicine 334, no. 20 (1996): 1305-1310; A. Schatzkin, ‘The Relationship of Inpatient Racial Composition and Hospital Closure in New York City,” Medical Care 22, no. 5 (1984): 379-387.
134.
L.A.Cooperet al., “Delving Below the Surface: Understanding how Race and Ethnicity Influence Relationships in Health Care,”Journal of General Internal Medicine21, no. S1 (2006): S21–S27; R.L. Johnson et al., “Racial and Ethnic Differences in Patient Perceptions of Bias and Cultural Competence in Health Care,” Journal of General Internal Medicine 19, no. 2 (2004): 101-110.
135.
D.H.Sorkin, Q.Ngo-Metzger, and I.De Alba, “Racial/Ethnic Discrimination in Health Care: Impact on Perceived Quality of Care,”Journal of General Internal Medicine25, no. 5 (2010): 390-396; T.C. Collins et al., “Racial Differences in How Patients Perceive Physician Communication Regarding Cardiac Testing,” Medical Care 40, no. 1 (2002): I27–I34; J. Malat, “Social Distance and Patients’ Rating of Healthcare Providers,” Journal of Health and Social Behavior 42, no. 4 (2001): 360-372; S. Saha et al., “Patient-Physician Racial Concordance and the Perceived Quality and Use of Health Care,” Archives of Internal Medicine 159, no. 9 (1999): 997-1004.
136.
J.Alvidrez, L.R.Snowden, and D.M.Kaiser, “The Experience of Stigma among Black Mental Health Consumers,”Journal of Health Care for the Poor and Underserved19, no. 3 (2008): 874-893.
137.
Id.
138.
The Center for Faith-based and Neighborhood Partnerships, U.S. Department of Health and Human Services, “A Practical Toolkit for Faith and Community Leaders in the Face of the Opioid Epidemic,”available at <http://www.ahecwest.org/uploads/files/Toolkit%20for%20community%20leaders.pdf> (last visited May 9, 2017). See also W. Bielefeld and W.S. Cleveland, “Defining Faith-Based Organizations and Understanding them Through Research,” Nonprofit and Voluntary Sector Quarterly 42, no. 3 (2013): 442-467; M. K. Campbell et al., “Church-based Health Promotion Interventions: Evidence and Lessons Learned,’ Annual Review of Public Health 28 (2007): 213-234.
139.
S.D.Molocket al., “Developing Suicide Prevention Programs for African American Youth in African American Churches,”Suicide and Life-Threatening Behavior38, no. 3 (2008): 323-333; T. Moore, “Promoting Change through the African American Church and Social Activism,” Journal of Psychology & Christianity 22, no. 4 (2003): 357-362; M. Sanders, “The Response of African American Communities to Alcohol and other Drug Problems: An Opportunity for Treatment Providers,” Alcoholism Treatment Quarterly 20, no. 3-4 (2002): 167-174; J.R. Morris and D.T. Robinson, “Community and Christianity in the Black Church,” Counseling and Values 41, no. 1 (1996): 59-69; T. Moore, “The African-American Church: A Source of Empowerment, Mutual Help, and Social Change,” Prevention in Human Services 10, no. 1 (1991): 147-167.
140.
B.Walton-Moss, E.M.Ray, and K.Woodruff, “Relationship of Spirituality or Religion to Recovery from Substance Abuse: A Systematic Review,”Journal of Addictions Nursing24, no. 4 (2013): 217-226; D.D. Chitwood, M.L. Weiss, and C.G. Leukefeld, “A Systematic Review of Recent Literature on Religiosity and Substance Use,” Journal of Drug Issues 38, no. 3 (2008): 653-688; K.S. Kendler et al., “Dimensions of Religiosity and their Relationship to Lifetime Psychiatric and Substance Use Disorders,” American Journal of Psychiatry 160, no. 3 (2003): 496-503; T.A. Wills, A.M. Yaeger, and J.M. Sandy, “Buffering Effect of Religiosity for Adolescent Substance Use,” Psychology of Addictive Behaviors 17, no. 1 (2003): 24-31; H.G. Koenig and D.B. Larson, “Religion and Mental Health: Evidence for an Association,” International Review of Psychiatry 13, no. 2 (2001): 67-78.
141.
G.J.Stahler, “A Faith-Based Intervention for Cocaine-Dependent Black Women,”Journal of Psychoactive Drugs39, no. 2 (2007): 183-190.
142.
B.T.Conneret al., “Effect of Religiosity and Spirituality on Drug Treatment Outcomes,”The Journal of Behavioral Health Services & Research36, no. 2 (2009): 189-198.
143.
T.Sisk, “Offering Syringes Along With Prayers, Churches Help IV Drug Users,”Kaiser Health News, Jan. 3, 2017.
144.
R.J.Tayloret al., “Black and White Differences in Religious Participation: A Multisample Comparison,”Journal for the Scientific Study of Religion35, no. 4 (1996): 403-410.
145.
L.M.Chatters, R.J.Taylor, and K.D.Lincoln, “African American Religious Participation: A Multi-Sample Comparison,”Journal for the Scientific Study of Religion38, no. 1 (1999): 132-145.
146.
J.S.Levin, R.J.Taylor, and L.M.Chatters, “A Multidimensional Measure of Religious Involvement for African Americans,”The Sociological Quarterly36, no. 1 (1995): 157-173.
147.
See Netherland and Hansen, supra note 103.
148.
See, e.g., K.Fiscella and M.R.Sanders, “Racial and Ethnic Disparities in the Quality of Health Care,”Annual Review of Public Health37 (2016): 375-394; W. Kennedy, G. Sonnad and S. Hing, “Putting Race Back on the Table: Racial Impact Statements,” Clearinghouse Review: Journal of Poverty Law and Policy 47 (2013): 154-162.
149.
C.London, “Racial Impact Statements: A Proactive Approach to Addressing Racial Disparities in Prison Populations,”Law & Inequality: A Journal of Theory and Practice29, no. 1 (2011): 211-248; M. Mauer, “Racial Impact Statements-Changing Policies to Address Disparities,” Criminal Justice 23, no. 4 (2009): 16-21.
150.
See Netherland and Hansen, supra note 103.
151.
See Netherland and Hansen, supra note 103.
152.
National Center for Health Statistics, Center for Disease Control and Prevention, “Drug Overdose Deaths in the United States, 1999–2015,”NCHS DATA BRIEF, no. 273 (Feb. 2017), available at <https://www.cdc.gov/nchs/data/databriefs/db273.pdf> (last visited May 7, 2018).
